Thomas Andrew Davis
Plus aucun poste en cours
Profil
Thomas Andrew Davis worked as a Senior Director-Clinical Science at Medarex, Inc. from 2001 to 2003.
He then worked as the Chief Medical Officer at GenVec, Inc. in 2005.
In 2006, he became the Chief Medical Officer & VP-Clinical Development at Celldex Research Corp.
and later became the Chief Medical Officer & Executive Vice President at Celldex Therapeutics, Inc. from 2014 to 2017.
In 2008, he briefly worked as the Chief Medical Officer & Senior Vice President at AVANT Immunotherapeutics, Inc. He then worked as the Chief Medical Officer at Gadeta BV from 2017 to 2018.
From 2018 to 2022, he worked as the Chief Medical Officer at Genocea Biosciences, Inc. Dr. Davis received his undergraduate degree from The Johns Hopkins University and his graduate and doctorate degrees from Georgetown University.
Anciens postes connus de Thomas Andrew Davis
| Sociétés | Poste | Fin |
|---|---|---|
| GENOCEA BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 20/05/2022 |
Gadeta BV
 Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Chief Tech/Sci/R&D Officer | 01/04/2018 |
| CELLDEX THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/09/2017 |
AVANT Immunotherapeutics, Inc.
 AVANT Immunotherapeutics, Inc. Medical SpecialtiesHealth Technology AVANT Immunotherapeutics, Inc. is a biopharmaceutical company. Discovers, develops and commercializes vaccines and therapeutics that address various applications including cardiovascular, viral and bacterial diseases. The company markets Rotarix for rotavirus infection and Megan Egg and Megan Vac 1 for Salmonella infection in chicken. It's immunotherapeutic products include TP10 for cardiac bypass surgery and CETi for cholesterol management. The company develops various bacterial vaccines including CholeraGarde for cholera, Ty800 for typhoid fever and Injectable Anthrax for anthrax infection. AVANT Immunotherapeutics has various products in preclinical development stages which include ETEC for Enterotoxigenic E coli infection, Shigella for dysentery, campylobacter for campylobacter infection, Oral Anthrax and Plague vaccines and other food safety and animal health vaccines. AVANT Immunotherapeutics was organized in 1983 and is headquartered in Needham, MA. | Chief Tech/Sci/R&D Officer | 01/10/2008 |
Celldex Research Corp.
 Celldex Research Corp. Miscellaneous Commercial ServicesCommercial Services Celldex Research Corp. engages in provision of biological research and development. The company is headquartered in Phillipsburg, NJ. | Chief Tech/Sci/R&D Officer | 01/03/2008 |
Formation de Thomas Andrew Davis
| The Johns Hopkins University | Undergraduate Degree |
| Georgetown University | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| CELLDEX THERAPEUTICS, INC. | Health Services |
| Entreprise privées | 5 |
|---|---|
Medarex, Inc.
 Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Commercial Services |
GenVec, Inc.
 GenVec, Inc. Pharmaceuticals: MajorHealth Technology GenVec, Inc. operated as a clinical-stage gene delivery company, which engaged in the development of therapeutics and vaccines. The firm designs, tests, and manufactured adenoviral-based product candidates using its proprietary AdenoVerse platform. Its products included CGF166-Hearing Loss; GV2311-RSV Vaccine; and GV2207-HSV-2 Immunotherapeutic. The company was founded in December 1992 and was headquartered in Rockville, MD. | Health Technology |
AVANT Immunotherapeutics, Inc.
AVANT Immunotherapeutics, Inc. Medical SpecialtiesHealth Technology AVANT Immunotherapeutics, Inc. is a biopharmaceutical company. Discovers, develops and commercializes vaccines and therapeutics that address various applications including cardiovascular, viral and bacterial diseases. The company markets Rotarix for rotavirus infection and Megan Egg and Megan Vac 1 for Salmonella infection in chicken. It's immunotherapeutic products include TP10 for cardiac bypass surgery and CETi for cholesterol management. The company develops various bacterial vaccines including CholeraGarde for cholera, Ty800 for typhoid fever and Injectable Anthrax for anthrax infection. AVANT Immunotherapeutics has various products in preclinical development stages which include ETEC for Enterotoxigenic E coli infection, Shigella for dysentery, campylobacter for campylobacter infection, Oral Anthrax and Plague vaccines and other food safety and animal health vaccines. AVANT Immunotherapeutics was organized in 1983 and is headquartered in Needham, MA. | Health Technology |
Celldex Research Corp.
Celldex Research Corp. Miscellaneous Commercial ServicesCommercial Services Celldex Research Corp. engages in provision of biological research and development. The company is headquartered in Phillipsburg, NJ. | Commercial Services |
Gadeta BV
Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Health Technology |
